Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07096674 · ClinicalTrials.gov registry record · Phase 2

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

A Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1, sponsored by Centessa Pharmaceuticals (UK) Limited.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
14
Study locations

NCT07096674 is a Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1 that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 90 participants, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (17% lower). The trial reports 14 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07096674, a Phase 2 study of Idiopathic Hypersomnia and Narcolepsy Type 1, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
14
Study locations

Study Summary

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

Conditions Studied

Idiopathic Hypersomnia Narcolepsy Type 1 Narcolepsy Type 2

Interventions

  • DRUG ORX750

Study Locations (14)

Georgia

  • Atlanta, Georgia - Atlanta
  • Atlanta, Georgia - Atlanta

North Carolina

  • Denver, North Carolina - Denver
  • Huntersville, North Carolina - Huntersville

Texas

  • Austin, Texas - Austin
  • El Paso, Texas - El Paso

Alabama

  • Auburn, alabama - Auburn

California

  • Santa Ana, California - Santa Ana

Florida

  • Miami, Florida - Miami

Michigan

  • Sterling Heights, Michigan - Sterling Heights

Nevada

  • Hendersen, Navada - Henderson

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-08-12
Est. Completion 2026-04-30
Phase Phase 2

Sponsor

Centessa Pharmaceuticals (UK) Limited

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07096674

The ClinicalTrials.gov registry entry for NCT07096674 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 7 other Idiopathic Hypersomnia trials with a reported enrollment target (17% lower). The listed sponsor is Centessa Pharmaceuticals (UK) Limited, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Idiopathic Hypersomnia appearing as the primary indexed condition, and to 1 intervention - of which ORX750 is the first listed.

NCT07096674 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Georgia, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT07096674 about?

NCT07096674 is a clinical study titled "A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia". This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

What is the current status of trial NCT07096674?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-08-12. Estimated completion is 2026-04-30.

What conditions does trial NCT07096674 study?

This clinical trial studies the following conditions: Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2.

What interventions are being tested in trial NCT07096674?

The interventions under investigation include: ORX750 (DRUG).

Who is sponsoring clinical trial NCT07096674?

This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07096674 being conducted?

This trial has 14 study locations across Alabama, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Hypersomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Hypersomnia

All registered trials for this condition

Narcolepsy Type 1

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.